Transthyretin-Related (attr) Familial Amyloid Cardiomyopathy Clinical Trials
2 recruiting trials for Transthyretin-Related (attr) Familial Amyloid Cardiomyopathy. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Transthyretin-Related (attr) Familial Amyloid Cardiomyopathy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Intellia Therapeutics (1), University of Texas Southwestern Medical Center (1), among the most active sponsors registered for these trials.
Track Transthyretin-Related (attr) Familial Amyloid Cardiomyopathy trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substitution at position 122 (V122I) in the transthyretin (TTR)...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Transthyretin-Related (attr) Familial Amyloid Cardiomyopathy, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Transthyretin-Related (attr) Familial Amyloid Cardiomyopathy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Transthyretin-Related (attr) Familial Amyloid Cardiomyopathy, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.